Please use this identifier to cite or link to this item: https://doi.org/10.1158/1535-7163.MCT-08-0071
Title: Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
Authors: Zhou, J. 
Lu, G.-D.
Ong, C.-S.
Ong, C.-N. 
Shen, H.-M. 
Issue Date: 2008
Citation: Zhou, J., Lu, G.-D., Ong, C.-S., Ong, C.-N., Shen, H.-M. (2008). Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Molecular Cancer Therapeutics 7 (7) : 2170-2180. ScholarBank@NUS Repository. https://doi.org/10.1158/1535-7163.MCT-08-0071
Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an importantmember of the tumor necrosis factor subfamily with great potential in cancer therapy. Andrographolide (Andro), a diterpenoid lactone isolated from a traditional herbal medicine Andrographis paniculata, is known to possess potent anti-inflammatory and anticancer activities. Here, we showed that pretreatment with Andro significantly enhances TRAIL-induced apoptosis in various human cancer cell lines, including those TRAIL-resistant cells. Such sensitization is achieved through transcriptional up-regulation of death receptor 4 (DR4), a death receptor of TRAIL. In search of the molecular mechanisms responsible for DR4 up-regulation, we found that the tumor suppressor p53 plays an essential role in DR4 transcriptional activation. Andro is capable of activating p53 via increased p53 phosphorylation and protein stabilization, a process mediated by enhanced reactive oxygen species production and subsequent c-Jun NH 2-terminal kinase activation. Pretreatment with an antioxidant (N-acetylcysteine) or a c-Jun NH2-terminal kinase inhibitor (SP600125) effectively prevented Andro-induced p53 activation and DR4 up-regulation and eventually blocked the Andro-induced sensitization on TRAIL-induced apoptosis. Taken together, these results present a novel anticancer effect of Andro and support its potential application in cancer therapy to overcome TRAIL resistance. Copyright © 2008 American Association for Cancer Research.
Source Title: Molecular Cancer Therapeutics
URI: http://scholarbank.nus.edu.sg/handle/10635/109177
ISSN: 15357163
DOI: 10.1158/1535-7163.MCT-08-0071
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.